In cancer, pathological angiogenesis is mediated by the vascular endothelial growth factor A (VEGFA) and angiopoietin-2 (ANGPT2), which both constitute good targets of anti-angiogenic therapies. This evidence concerns the gene ANGPT2 and cancer.